{"id":"W3083253396","doi":"10.1158/1538-7445.am2020-lb-258","title":"Abstract LB-258: Efficacy of first-line (1L) pembrolizumab by PD-L1 combined positive score <1, 1-19, and ≥20 in recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): KEYNOTE-048 subgroup analysis","year":2020,"lang":"en","type":"article","venue":"Cancer Research","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"ca_institutions":"Institute of Cancer Research; Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Pembrolizumab; Hazard ratio; Internal medicine; Proportional hazards model; Population; Cetuximab; Oncology; Progression-free survival; Post-hoc analysis; Head and neck cancer; Confidence interval; Subgroup analysis; Urology; Overall survival; Gastroenterology; Nuclear medicine; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003384164,0.001384228,0.003287027,0.0006216217,0.0002706473,0.001087682,0.000969074,0.0007842201,0.006011375],"category_scores_gemma":[0.002247897,0.0004290046,0.005996577,0.0004861129,0.0004111316,0.0007067049,0.0006347434,0.001433405,0.0007925542],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009821946,"about_ca_system_score_gemma":0.0009018892,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009083563,"about_ca_topic_score_gemma":0.002159396,"domain_scores_codex":[0.9985435,0.0006826213,0.0002167117,0.0002686094,0.0001636347,0.0001249074],"domain_scores_gemma":[0.999166,0.0001985052,0.0002506236,0.000164444,0.00008570967,0.0001346608],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.9236238,0.001469323,0.01146305,0.001797202,0.02140678,0.0001015571,0.00005550053,0.001038047,0.01036807,0.0001163421,0.003571927,0.02498846],"study_design_scores_gemma":[0.6470142,0.1466264,0.1171944,0.0004336072,0.0632172,0.0005015911,0.0002075464,0.005361562,0.01024655,0.001229145,0.007781486,0.0001864007],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9710768,0.01310884,0.001383245,0.0005173408,0.0003103424,0.002584149,0.008097636,0.0001991391,0.002722599],"genre_scores_gemma":[0.990519,0.0009324353,0.0007210803,0.0003497319,0.0001567456,0.001262425,0.004233683,0.00003335436,0.001791677],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006011375,"threshold_uncertainty_score":0.02011001,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08650490551771019,"score_gpt":0.3783165749683259,"score_spread":0.2918116694506158,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}